A systematic review of methodological quality of model development studies predicting prognostic outcome for resectable pancreatic cancer

被引:14
作者
Bradley, Alison [1 ,2 ]
Van der Meer, Robert [1 ]
McKay, Colin J. [2 ]
机构
[1] Univ Strathclyde, Sch Business, Management Sci, Glasgow, Lanark, Scotland
[2] Glasgow Royal Infirm, West Scotland Pancreat Unit, Glasgow, Lanark, Scotland
关键词
hepatobiliary surgery; pancreatic surgery; predictive modeling; risk management; DUCTAL ADENOCARCINOMA; REGRESSION; RESECTION; SURVIVAL; NOMOGRAM; EVENTS; SIMULATION; MANAGEMENT; MORTALITY; RATIO;
D O I
10.1136/bmjopen-2018-027192
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To assess the methodological quality of prognostic model development studies pertaining to post resection prognosis of pancreatic ductal adenocarcinoma (PDAC). Design/setting A narrative systematic review of international peer reviewed journals Data source Searches were conducted of: MEDLINE, Embase, PubMed, Cochrane database and Google Scholar for predictive modelling studies applied to the outcome of prognosis for patients with PDAC post resection. Predictive modelling studies in this context included prediction model development studies with and without external validation and external validation studies with model updating. Data was extracted following the Checklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) checklist. Primary and secondary outcome measures Primary outcomes were all components of the CHARMS checklist. Secondary outcomes included frequency of variables included across predictive models. Results 263 studies underwent full text review. 15 studies met the inclusion criteria. 3 studies underwent external validation. Multivariable Cox proportional hazard regression was the most commonly employed modelling method (n=13). 10 studies were based on single centre databases. Five used prospective databases, seven used retrospective databases and three used cancer data registry. The mean number of candidate predictors was 19.47 (range 7 to 50). The most commonly included variables were tumour grade (n=9), age (n=8), tumour stage (n=7) and tumour size (n=5). Mean sample size was 1367 (range 50 to 6400). 5 studies reached statistical power. None of the studies reported blinding of outcome measurement for predictor values. The most common form of presentation was nomograms (n=5) and prognostic scores (n=5) followed by prognostic calculators (n=3) and prognostic index (n=2). Conclusions Areas for improvement in future predictive model development have been highlighted relating to: general aspects of model development and reporting, applicability of models and sources of bias. Trial registration number CRD42018105942
引用
收藏
页数:9
相关论文
共 53 条
[1]   Primer: an evidence-based approach to prognostic markers [J].
Altman, DG ;
Riley, RD .
NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (09) :466-472
[2]   Methodological challenges in the evaluation of prognostic factors in breast cancer [J].
Altman, DG ;
Lyman, GH .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) :289-303
[3]   Systematic reviews in health care - Systematic reviews of evaluations of prognostic variables [J].
Altman, DG .
BMJ-BRITISH MEDICAL JOURNAL, 2001, 323 (7306) :224-228
[4]   The revised CONSORT statement for reporting randomized trials: Explanation and elaboration [J].
Altman, DG ;
Schulz, KF ;
Moher, D ;
Egger, M ;
Davidoff, F ;
Elbourne, D ;
Gotzsche, PC ;
Lang, T .
ANNALS OF INTERNAL MEDICINE, 2001, 134 (08) :663-694
[5]   Prognosis and prognostic research: validating a prognostic model [J].
Altman, Douglas G. ;
Vergouwe, Yvonne ;
Royston, Patrick ;
Moons, Karel G. M. .
BMJ-BRITISH MEDICAL JOURNAL, 2009, 338 :1432-1435
[6]  
[Anonymous], BREAST CANCER TRANSL
[7]  
[Anonymous], HPB
[8]  
[Anonymous], CANC INFORM
[9]  
[Anonymous], PANCR CANC UK POL BR
[10]  
Ashley SW, 2012, CURR PROB SURG, V49, P731, DOI 10.1067/j.cpsurg.2012.08.002